Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($1.05), $0.05 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $25.37 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Nvidia pitches Vera CPU to Chinese clients with August delivery target